Dan G. Duda, DMD, PhD, Director of Translational Research in GI Radiation Oncology, Investigator, Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Associate Professor of Tumor Biology, Harvard Medical School, Charlestown, MA, USA.
Dr. Duda’s area of research is tumor interaction with its microenvironment and its impact on resistance to immunotherapy, antiangiogenesis and cytotoxic therapies. Over the last decade and a half, he built an independent and strong Liver Cancer Research Program. The translational goal of this program increasing the durability of response to available therapies. The basic research goal is to identifying new cellular and molecular mechanisms of local and metastatic tumor progression and treatment resistance and validate them as new targets for cancer treatment.To this end, his group studying the activity in this combinatorial setting of antiangiogenic drugs, antifibrotic drugs or radiotherapy approaches using preclinical studies that reproduce the hallmarks of human cancers. In parallel, they are conducting studies of biomarkers of response in correlative clinical studies in cancer patients He has authored over 225 publications so far, of which 140+ are original reports, including in basic research journals such as Nature, Nature Medicine, Nature Biotechnology, Nature Genetics, Cell, Cancer Cell, and Science Translational Medicine, and in clinical journals such as Journal of Clinical Oncology and JAMA Oncology.
He is a Founding Editor of the Surgery, Gastroenetrology and Oncology, a Senior Associate Editor of the International Journal of Radiation Oncology*Biology*Physics, and an Editorial Board member for several other journals, including Clinical & Translational Radiation Oncology, Journal of Hepatocellular Carcinoma and Cancers. Heis currently serving as the Secretary General of the IASGO.Dr. Duda was elected as an Honorary Member of the Academy of Medical Sciences of Romania in 2012, and in the College of Fellows of the American Institute for Medical and Biomedical Engineering in 2020.